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Abstract: The development of antibiotic resistance is usually associated with genetic 
changes, either to the acquisition of resistance genes, or to mutations in elements relevant 
for the activity of the antibiotic. However, in some situations resistance can be achieved 
without any genetic alteration; this is called phenotypic resistance. Non-inherited resistance 
is associated to specific processes such as growth in biofilms, a stationary growth phase or 
persistence. These situations might occur during infection but they are not usually 
considered in classical susceptibility tests at the clinical microbiology laboratories. Recent 
work has also shown that the susceptibility to antibiotics is highly dependent on the 
bacterial metabolism and that global metabolic regulators can modulate this phenotype. 
This modulation includes situations in which bacteria can be more resistant or more 
susceptible to antibiotics. Understanding these processes will thus help in establishing 
novel therapeutic approaches based on the actual susceptibility shown by bacteria during 
infection, which might differ from that determined in the laboratory. In this review, we 
discuss different examples of phenotypic resistance and the mechanisms that regulate the 
crosstalk between bacterial metabolism and the susceptibility to antibiotics. Finally, 
information on strategies currently under development for diminishing the phenotypic 
resistance to antibiotics of bacterial pathogens is presented. 
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1. Introduction 
Most studies on the development of antibiotic resistance deal with inheritable resistance. Under this 
view, the acquisition of a resistance phenotype requires a genetic change; either mutations (including 
point mutations, deletions and insertions), or the acquisition by horizontal gene transfer of antibiotic 
resistance genes [1–5]. However, other situations in which bacteria become transiently resistant to 
antibiotics, in the absence of a genetic change, have been also described [6]. Among them, the most 
studied are drug indifference, the growth in biofilms, and the phenomenon of persistence. However, 
there are other situations wherein bacteria present changes in their susceptibility to antibiotics 
depending on their metabolic state. Whilst this phenotype of resistance to antibiotics has been in 
occasions attributed to a situation of growth arrest that precludes the activity of some bactericidal 
antibiotics as beta-lactams, a growing number of evidences indicates that the link between the 
metabolic state of bacterial populations and their phenotype of susceptibility to antibiotics is far more 
complex. Although increased resistance can also be achieved because of the induction of specific 
resistance mechanisms (for instance induction of chromosomally-encoded -lactamases by -lactams [7]), 
this topic is not usually considered as phenotypic resistance and will not be discussed in the article. 
Some recent works have analyzed the determinants that contribute to the intrinsic resistance 
(intrinsic resistome) of bacterial pathogens [8–16]. Notably, in all cases in which a comprehensive study 
has been performed the number of genes involved in the phenotype of resistance is larger than could be 
predicted if they had evolved as specific elements for counteracting the action of the drugs. Furthermore, 
several of such genes encode key elements of the bacterial metabolism. Altogether, these results 
indicate that the specific phenotype of susceptibility to antibiotics is under metabolic control and hence 
that changes in the bacterial metabolism can consequently alter the susceptibility to antibiotics [17,18].  
The fact that the susceptibility to antibiotics can change depending on the bacterial metabolic state 
is a two-way road. Bacteria can be transiently more resistant to antibiotics, a situation that may 
compromise therapy. Conversely, there can be specific metabolic conditions that increase the 
susceptibility to antibiotics. This situation has been recently exploited for developing nutritionally-
based strategies for fighting persistent cells [19]. Similarly, the comparison of the metabolism of 
Mycobacterium tuberculosis in vitro and in vivo has served to understand the reasons why some lead 
compounds with very good activity in vitro and good pharmacological properties were not useful in a 
tuberculosis model of infection. The understanding of the causes of this phenotypic resistance, which 
is due to differences in the carbon metabolism of M. tuberculosis in vivo and in vitro, is important for 
the development of novel anti-tuberculosis antibiotics [20]. 
Several articles have reviewed the acquisition of antibiotic resistance determinants by human 
pathogens. However, information on phenotypic resistance is lower in comparison. In the current 
article, some specific examples of situations that produce a transient, non-inherited, state of antibiotic 
resistance are reviewed.  
2. Drug Indifference 
Soon after the introduction of antibiotics for treating infections, it was described that resting cells 
are less susceptible to penicillin [21], a situation (Figure 1) that was named ‗drug indifference‘ [22]. Some 
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recent works have shown that this effect is specific for the type of antibiotic considered. Non-dividing 
cells are fully resistant to ampicillin and tetracycline, whereas ciprofloxacin and streptomycin are active 
against stationary cells although their level of activity is lower than when cells are actively growing [6]. 
Figure 1. Some situations of transient changes of bacterial susceptibility to antibiotics are 
described. (A) Drug indifference occurs when the antibiotic is effective only in a specific 
bacterial physiological condition. This situation was first described for β-lactam antibiotics 
that do not kill non-dividing growing cells; (B) In a bacterial population, there is a 
subpopulation of cells called persistents that are not killed by antibiotics in conditions that 
kill the bulk of the population. Once growth resumes, these persistent bacteria become 
susceptible to antibiotics, indicating that the phenotype of resistance is transient, not being 
the consequence of a genetic change; (C) Bacteria usually grow forming biofilms when 
attached to surfaces and under these conditions they are more resistant to antibiotics. 
Gradients of nutrients and of oxygen cause different metabolic states in the bacteria 
depending on their depth inside the biofilm, which can affect their susceptibility to 
antibiotics. Moreover, compounds of the matrix can impair the diffusion of the antibiotic 
and eventually bind the drug thus reducing its free concentration. Quorum sensing, which 
can be triggered at dense regions of the biofilm, may also alter bacterial susceptibility to 
antibiotics. (D) Bacteria change their permeability to antibiotics in response to several 
environmental and internal factors such as temperature, the presence of specific inducers, 
reactive oxygen species (ROS) or specific metabolic situations. Changes can affect 
antibiotic susceptibility at several levels. First, reducing the binding of the antibiotic by 
modification of the lipopolysaccharide (LPS), or generating outer membrane vesicles that 
give rise to more surface and minimizes the effective amount of the antibiotic per cell. 
Second, modifying the number or type of bacterial porins, the aqueous channels used by 
the antibiotic to penetrate inside bacteria, might help keeping the antibiotics out of the cell. 
Third, expressing multiple efflux pumps that extrude the antibiotic once it has reached the 
cytoplasm decreases the toxic activity of the antibiotic. 
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The reduced susceptibility to antimicrobials that depends on the growth rate can be relevant for 
bacteria growing at host locations where growth is restricted or in situations where the bacteria have 
made use of the nutritional resources provided by the host and hence growth rate is reduced. This 
might be particularly relevant for long-lasting infections. In fact, it has been described that the antibiotic 
concentrations required for curing an infection are directly related to the duration of the infection [23]. 
Further works using a model in which mice were infected with a mixture of susceptible and resistant 
bacteria showed that during infection bacteria become increasingly refractory to treatment [24]. This 
reduced susceptibility is not inheritable and is the consequence of changes in the bacterial physiology. 
More recently, it has been shown that eight hours after infection bacteria are in a resting situation [6], 
which can cause the observed drug indifference, at least in this experimental model of infection. 
These finding are of relevance for the treatment of human infections. It has been suggested that the 
existence of drug indifferent, slow growing (or resting) cells can be the cause of relapse after antibiotic 
treatment that can be observed for some bacterial infections [25,26]. It has been stated as well that this 
low susceptibility is the cause for the need of using very long treatments for slow-growing bacteria as 
Mycobacterium leprae [27] or Mycobacterium tuberculosis [28]. Finding drugs that can act on these 
‗drug refractory‘ cells is thus of interest for the treatment of long lasting infections or infections due to 
slow-growing pathogens. An example of this view is the potential use of antibiotics that specifically 
kill anaerobes for the treatment of infections by M. tuberculosis, since it has been described that 
dormant, hypoxic M. tuberculosis cells are resistant to isoniazid, but susceptible to metronidazol [29–31].  
3. Biofilms 
Although most studies on bacterial susceptibility to antibiotics are performed using bacteria 
growing planktonically, microorganisms can grow forming biofilms when they are attached to a 
surface [32–35]. For human pathogens, this situation can be particularly relevant in the case of chronic 
infections of prosthetic devices. Different works have shown that bacteria forming biofilms are less 
susceptible to antibiotics than those growing planktonically [36–43]. Furthermore, it has been 
described that subinhibitory concentrations of antibiotics can trigger the formation of biofilms by 
bacterial populations [44,45], suggesting that antibiotics can induce transient, non-specific resistance 
to themselves. There are several potential reasons why biofilms are more resistant to antibiotics 
(Figure 1). The most obvious one is that biofilms are complex structures in which the free diffusion of 
compounds as antibiotics [46,47] is more difficult that in liquid cultures (planktonic cells). The 
capability to diffuse into the biofilm will differ depending on the structure of the antibiotic [48]. 
Increasing the diffusion of the antibiotics inside biofilms might thus help in enhancing their activity [49]. 
However, this would be just a part of the problem [50]; in several occasions the speed in the 
penetration of the antibiotics into the biofilm does not seem to be the key element for explaining the 
phenotype of resistance [51]. The biofilm structure itself may contain elements that bind antibiotics, 
sequestering them and hence reducing the freely available concentration of these compounds within 
the biofilm structure.  
More recent articles have focused on the metabolic state of bacteria when growing forming 
biofilms. It has been suggested that the biofilm-forming microorganisms can display different 
metabolic situations, including actively growing cells that should be killed by antibiotics and resting 
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cells that would be transiently resistant to these compounds. These resting cells might be a 
subpopulation of persisters (see below) present in any biofilm [52]. The different metabolic situation 
of each subpopulation is highly dependent on the oxygen and nutrients availability, which is higher at 
the upper layers of the biofilm and lower at the deeper ones [53,54]. Surprisingly, the effect of these 
metabolic situations is different depending on the antibiotic family. It has been found that the aerobic 
regions of Pseudomonas aeruginosa biofilms are susceptible to quinolones and resistant to cationic 
peptides whereas the opposite occurs at the hypoxic regions [55]. One of the potential causes of the 
resistance to cationic peptides of biofilms relies on their structure itself. One of the compounds 
forming the biofilm extracellular matrix is DNA. This macromolecule chelates cations, and reduced 
concentrations of divalent cations trigger expression of the master sensor regulator of resistance to 
cationic peptides PhoP-PhoQ [56]. It has been then suggested that the use of DNase, which can break 
the biofilm matrix, may increase biofilm susceptibility to antibiotics [57]. In addition to the effect of 
metabolic changes on the susceptibility to antibiotics to biofilm-growing bacteria, classical resistance 
determinants may also be involved in the phenotype of resistance. For instance, the efflux pump 
MexAB-OprM contributes to the lack of susceptibility of P. aeruginosa biofilms [58], whilst it is not 
relevant in the case of planktonic cells.  
Altogether, these results indicate that there are several, simultaneous mechanisms that alter the 
susceptibility to antibiotics of bacteria growing in biofilms. Understanding the signals and mechanisms 
involved in the formation of biofilms can thus help in eliminating them. In the case of P. aeruginosa, 
the quorum sensing (QS) response triggers biofilm formation. Inhibition of QS thus reduces the 
formation of biofilm and consequently increases susceptibility to antibiotics. One of the compounds 
that inhibits biofilm formation is the macrolide azithromycin [59]. Although Gram-negative bacteria as 
P. aeruginosa are intrinsically resistant to macrolides, azithromycin has been proposed as a drug of 
choice for the treatment of chronic P. aeruginosa infections given its strong anti-QS and anti-biofilm 
activity [60,61]. 
4. Transient Changes in Bacterial Permeability to Antibiotics 
One of the main factors in the effectiveness of the antibiotics is their penetration inside the bacterial 
cell. This means that the first barrier against antibiotics consists on the bacterial envelopes. 
Consequently, changes in bacterial permeability may affect the susceptibility to antibiotics [62,63]. 
The permeability to antibiotics of microorganisms can be modulated by means of three different 
mechanisms (Figure 1). First, bacteria may alter their surface by modifying the lipopolysaccharide, 
reducing the molecular interactions with the antibiotic, and consequently, its penetration. Production of 
membrane vesicles increases the available membrane surface, which can also reduce the effective 
concentration of antibiotic available to enter the cell. Second, alterations in the number or type of 
porins or antibiotic transporters may change the susceptibility to antibiotics. Third, once the antibiotic 
reaches the cytosol, it can be pumped actively outside the cell through efflux pumps.  
In Gram-negative bacteria, the first barrier to antibiotic penetration is the outer membrane, mainly 
composed in its outer face by the lipopolysaccharide (LPS). The LPS presents anionic groups where 
the cationic antibiotics bind, representing the first step of antibiotic uptake [64].  
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In P. aeruginosa, it has been described that the alteration of the negative charge of the lipid A of the 
LPS by adding 4-aminoarabinose, increases the resistance to polymyxin, aminoglycosides and cationic 
antimicrobial peptides. This response can be induced by limiting concentrations of the divalent cations 
Mg
2+
 and Ca
2+
, or of polymyxin and cationic antimicrobial peptides. In P. aeruginosa, there are at least 
three two-component systems (PhoP-PhoQ [65,66], PmrA-PmrB [67], and ParS-ParR [68]) that 
upregulate the arnBCADTEF operon, whose products are responsible for the changes in the LPS. The 
induction of resistance to cationic antibiotics by environments with low amounts of Mg
2+
 has been also 
described in Salmonella typhimurium [69]. Especially relevant in the clinic is the induction of antibiotic 
resistance by host-defense peptides belonging to innate human defense [70], and for the new peptides 
that are being developed to be used in the frame of novel anti-infective therapeutic strategies [71]. 
A similar phenomenon of LPS modification leading to transient resistance to aminoglycosides has 
been described in Stenotrophomonas maltophilia [72]. The authors found a correlation between the 
LPS pattern and an increase in the resistance to aminoglycosides when the bacteria were grown at 30 °C. 
Although the molecular basis of transient induction of resistance in such conditions has not been 
clarified, these results strongly suggest that the growth temperature affects the LPS composition 
challenging the binding or the uptake of aminoglycosides. 
Another mechanism that might transiently induce resistance in Gram-negative microorganisms is 
the formation of Outer Membrane Vesicles (OMVs). It has been proposed that OMVs can trigger an 
initial defense mechanism against different environmental stresses including antibiotics [73]. OMVs 
are made with fragments of the bacterial outer membrane enclosing periplasm and active proteins. 
Among the roles that OMVs might play, it has been suggested that they are involved in secretion, 
intercellular signal trafficking and in bacterial survival-related functions [74]. Like LPS, OMVs can 
bind cationic peptides and antibiotics, which suggests that they can provide transient resistance to 
these compounds just by a trapping mechanism that reduces the free concentration of the drug [73].  
It is known that some factors like temperature and nutrient limitation can increase the production of 
OMVs. Furthermore, the composition and number of OMVs are different in biofilms and in planktonic 
cultures [73]. Whether or not induction of OMVs formation under such environmental conditions can 
induce transient antibiotic resistance is still an open question that merits to be explored. 
To enter into bacterial cells, antibiotics can make use of regular transporters (porins and inner 
membrane transporters) used for the microorganisms to allow the entrance of different substrates, 
including nutrients [63,75]. Escherichia coli harbors two main porins, OmpC and OmpF. These two 
porins are involved in the transport of some antibiotics such as quinolones, tetracycline, chloramphenicol 
or β-lactams. Low-level expression or inactivation of porins impairs the intracellular accumulation of 
the antibiotic and consequently renders resistance [75]. This implies that changes in the expression of 
porins due to environmental signals may alter bacterial susceptibility to antibiotics [62]. It has been 
described that OmpC and OmpF are inversely regulated. OmpF is highly produced in environments 
with low osmolarity and temperature, whereas OmpC is the prevailing porin when bacteria are 
growing under conditions of high osmolarity and high temperature, like for example when they are 
colonizing a nutrient-rich animal gut [76]. Since each porin has different substrates profile, the 
consequences of this regulation for antibiotic resistance will have some degree of specificity [75]. The 
expression of porins is finely tuned in response to changes in the environment; because of this, they are 
under control of complex regulatory networks. The phosphorelay system EnvZ-OmpR senses 
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osmolarity and controls at the transcriptional level the OmpF/OmpC ratio [77,78]. On top of this 
regulation, there are two small antisense RNAs (micF [79] and micC [80]) which participate in the 
post-transcriptional regulation of OmpF and OmpC, respectively. micF is known to respond to changes 
in osmolarity [81], temperature [82] and nutrient availability [83], and is the link to other regulatory 
networks such as the Mar-Sox-Rob regulon, which responds to salicylate [84]. In this way, fast 
changes in the environment can be rapidly faced up by the microorganisms and this has consequences 
in bacterial susceptibility to antibiotics. 
As above stated, multidrug efflux pumps can extrude a broad range of substrates chemically 
different, including antibiotics [85–90]. Genomic studies have shown that multidrug efflux pumps can 
account for 10% of all transporters in some bacterial species [91–93]. Together with their high 
conservation, this suggests that efflux pumps have important roles for the bacterial physiology in 
addition to being antibiotic resistance determinants [89,90]. Expression of efflux pumps is usually 
tightly down-regulated, which means that transient expression is achieved just in the presence of the 
right effectors [94,95]. Among those effectors that trigger expression of MDR efflux pumps, some 
might be relevant during infections. These include biocides such as triclosan, which is found in several 
products from soaps to toothpastes, and which has been shown to induce transiently the expression of 
the SmeDEF efflux pump from S. maltophilia [96]. More relevant from the therapeutic point of view is 
the induction of efflux pumps (and consequently resistance) in the presence of bile, cationic peptides 
or fatty acids [97–101], because bacteria can encounter these compounds and therefore might display a 
phenotype of transient resistance in the course of an infection.  
In addition to their induction by specific effectors, expression of efflux pumps can be altered by 
more general changes to their habitat. For example, it has been described that oxidative and 
nitrosidative stress [102] might alter the expression of multidrug efflux pumps. In E. coli, the exposure 
to oxidative agents like paraquat, which produces anion superoxide O
2−
, induces the SoxRS operon. As 
a consequence, the expression of the AcrAB-TolC multidrug efflux system is induced [103] and 
bacteria become transiently antibiotic resistant. In P. aeruginosa, another regulator, MexR, which is 
the repressor of mexAB-oprM MDR efflux pump, is directly oxidized by oxidative agents. As a 
consequence, MexAB-OprM is overexpressed leading to transient antibiotic resistance [104]. A similar 
response to oxidative and nitrosidative stress has been described for other P. aeruginosa efflux pumps, 
like MexXY-OprM [105], and MexEF-OprN [106]. Since bacteria can face oxidative and nitrosative 
stress during infection, it is likely that these efflux pumps are overexpressed and bacteria present a 
phenotype of reduced susceptibility to antibiotics in this situation. However, this topic has not yet been 
addressed in detail. 
We have presented examples in which changes in membrane permeability trigger transient antibiotic 
resistance. However, the opposite might also happen. In some cases, in vivo growing conditions can 
lead to an increase in antibiotic susceptibility allowing a better response to anti-infective therapy. This 
is the case of susceptibility to fosfomycin of Listeria monocytogenes [107]. Listeria is an intracellular 
pathogen. In vitro, Listeria is resistant to fosfomycin. However, it has been shown that when growing 
inside the host cells L. monocytogenes becomes susceptible to this antibiotic. Fosfomycin enters in 
bacteria using Hpt, the same transporter as hexoses-phosphate and glycerol-phosphate [108]. The Hpt 
transporter is controlled by the global regulator of virulence, PfrA, which is highly expressed during 
macrophage infection [107,109]. One of the nutrients that L. monocytogenes uses at the intracellular 
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milieu is glucose-phosphate. For an efficient uptake of this nutrient, the expression of its transporter 
Hpt is induced in intracellular bacteria, hence causing the observed increased susceptibility to 
fosfomycin. In this way, an antibiotic whose use has been discarded based on classic susceptibility 
tests, would have a potential use in clinics, to treat Listeria infections. 
From these results, it is clear that the metabolic status of the microorganisms is of relevance for 
their susceptibility to antibiotics [17]. It is thus possible that global metabolic regulators may also 
modulate the antibiotic resistance. This is the case of Crc, a global post-transcriptional regulator of 
carbon metabolism in P. aeruginosa [110–113]. It has been described that in addition to regulating the 
utilization of alternative carbon sources in nutrient-rich environments, Crc modulates the virulence and 
antibiotic susceptibility of P. aeruginosa [18]. Bacterial transporters are targets for Crc. For example, 
the expression of the OprD2 protein, involved in the uptake of basic amino acids and of the antibiotic 
imipenem, and of GlpT, involved in the uptake of glycerol phosphate and of the antibiotic fosfomycin, 
are downregulated by Crc. As a consequence, a Crc defective P. aeruginosa mutant is more 
susceptible to these antibiotics. This makes Crc a good target in the search of drugs, to be used in 
combination, for enhancing the activity of antibiotics currently in use.  
5. Inoculum Size and Phenotypic Resistance 
Several reports have shown that the size of the bacterial inoculum is important for the activity of 
antibiotics [114–117]. It has been suggested that this effect can be the cause of the failure for treating 
infections with a high bacterial load, because the actual minimal inhibitory concentrations of such 
bacterial populations are higher than those determined using classical laboratory tests [115,118]. In the 
case of bacteria producing antibiotic-inactivating enzymes, this effect is due to the activity of the 
enzyme that degrades the antibiotic at higher rates when more cells are present [116,117,119]. 
However, the situation is less clear in the case of bacteria that do not harbor a mechanism of resistance 
that involves the degradation of the antimicrobial. For these microorganisms and antibiotics, two 
situations can be envisaged. One is a reduction in the antibiotic concentration at high cell densities due 
to its binding to cell envelopes and debris of alive and killed cells. Another is the existence of less 
molecules of antibiotic per cell at high cellular density. Using experimental approaches and 
mathematical modeling, it has been shown that most likely both situations are relevant for inoculum-
dependent antibiotic resistance [120], and that other processes can be important for this phenotype. 
Taken into consideration that high cell densities trigger the QS response and the fact that QS might 
affect the susceptibility to antibiotics it is worth considering that the QS response might have a role in 
the inoculum-dependent antibiotics susceptibility of bacterial populations. Nevertheless, to the best of 
our knowledge, this possibility has not yet been explored. 
6. Persistence 
Persistence to antibiotic treatment has been described for several different bacterial species, and 
consists (Figure 1) on a situation in which a subpopulation of the bulk of bacteria under treatment 
presents a refractory state to the action of antibiotics [121–123]. The relative fraction of cells in this 
situation can range from 10
−6
 for exponentially growing bacteria to 10
−2
 for bacteria in the stationary 
growth phase. Resistance is transient; persistent cells resume growth once the antibiotic is removed, 
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but are killed at a similar rate as the original susceptible population if the antibiotic is added again [124]. 
For most infections, phenotypic resistance to antibiotics of a very small number of cells is not 
problematic, since these cells are removed by the action of the immune system. However, there are 
situations in which persistence can be a relevant problem for the success of the treatment of the infection. 
One possible explanation for persistence is that, in any bacterial population, a fraction of the cells is 
in a non-dividing (dormant) situation that makes them refractory to the action of the antibiotics. 
However, the situation is more complex [125], with a number of global regulators and metabolic 
enzymes involved in the process [126,127]. Whilst bacterial cultures can contain a subpopulation of 
pre-existing dormant cells (Type I persisters), there is another subpopulation (Type II persisters) that 
emerges as the consequence of the inherent bistability of growing cells, from normal to persisters [121]. 
The main factor triggering Type I persistence is starvation. Nevertheless, the phenomenon is not a 
direct response to a non-growing situation of bacterial cells. On the contrary, the fact that Type I 
persisters are fully susceptible to antibiotics in a short time window after the beginning of growth of 
the whole population indicates that persistence consists on a metabolic shift that occurs after the 
stationary phase is over [128]. One of the key elements for the establishment of Type I persistence is 
the stringent response as shown by the relevant role that SpoT and RelA have for persistence in  
E. coli [129]. However, some different works have shown that there are different mechanisms 
triggering persistence, among them the inherent bimodal distribution of toxin/antitoxin proteins that 
can render non-uniform bacterial populations in which those cells containing high levels of toxin arrest 
their growth for long periods of time [39,130,131]. It is important to notice that infection-linked 
situations can trigger persistence. For instance, quinolones can induce persistence in E. coli through 
the SOS-mediated induction of the toxin TisB [132] and intracellular pathogens can present non-
dividing, persistent, subpopulations when growing inside their host cells [133]. 
The increased knowledge on the mechanisms of persistence has led to propose different approaches 
for eradicating these bacterial subpopulations that are refractory to antibiotic treatment. In the case of 
P. aeruginosa, it has been described that the QS response is relevant for persistence [134]. 
Inhibition of QS has been suggested as an anti-virulence approach for fighting P. aeruginosa 
infections [135,136]. Reduction of the fraction of persistent cells or enhancing their susceptibility to 
antibiotics by this kind of inhibitors will also be of benefit for the treatment of P. aeruginosa infections. 
Recent work has shown that the QS inhibitor (Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one 
restores the antibiotic susceptibility of P. aeruginosa PAO1 persisters. However, the effect is not due 
to the inhibition of QS and the mechanisms for this activity remain to be fully determined [137]. 
Some works have shown that the knockout of genes coding for metabolic enzymes, such as ygfA 
that encodes an enzyme involved in folate biosynthesis or yigB, encoding a flavin mononucleotide 
phosphatase decreases persistence [126], whereas their overexpression, increases tolerance. Given that 
persistence can be under metabolic control, another approach for eliminating persisters is by shifting 
the bacterial metabolism. The feasibility of this approach has been demonstrated in a set of recently 
published articles. In one of them, the authors were able to kill persister cells with aminoglycosides 
just by adding specific metabolic substrates that allow the recovery of bacterial proton motive force 
without resuming growth [19]. Following the same approach, it has been found that the addition of  
3-[4-(4-methoxyphenyl)piperazin-1-yl]piperidin-4-yl biphenyl-4-carboxylate to bacterial cultures 
causes the reversion of persisters to antibiotic-sensitive cells [138]. 
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A recent article explored another possibility for eradicating persisters. It was observed that  
M. tuberculosis persisters require a small reduction in oxygen availability for their survival to 
antibiotics. At high concentrations of oxygen, persisters were killed at the same rate as normal cells. 
Since his situation could be a consequence of a reduced capability of persisters to generate reactive 
oxygen species (ROS) in the presence of bactericidal antibiotics, priming ROS generation will 
eliminate persisters. In line with this reasoning, the authors demonstrated that antibiotic clofazimine, 
which increases ROS, successfully eradicates the persister population [139]. 
7. Concluding Remarks 
Most studies on the mechanisms of antibiotic resistance address the development of resistance as 
the consequence of a genetic, inheritable change, which can be a mutation or the acquisition of a 
resistance gene. These are off/on directional situations; bacteria are either susceptible or resistant and 
reversion from resistance to susceptibility is not a frequent event. Several works have shown that this 
is a part of the resistance landscape and that there are situations in which resistance is not driven by a 
genetic change. Transient, reversible resistance can be achieved by different mechanisms, which are 
linked to the physiological state of bacteria and to the inputs that microorganisms receive when 
confronted to different habitats and stressors. The study of the mechanisms of phenotypic resistance is 
of relevance to understand the reasons of therapeutic failures for bacteria that are classified as 
susceptible using classical testing methods, but also to increase the susceptibility to antibiotics of 
bacterial pathogens.  
Classical methods for improving the efficacy of antibiotics are mostly based on the development of 
permeabilizers and of inhibitors of mechanisms of resistance, mainly of antibiotic inactivating 
enzymes and of multidrug efflux pumps [9,140–142]. The study of the mechanisms leading to 
phenotypic resistance may also serve for this purpose. As stated in the review, this knowledge may 
serve, among other issues, to eliminate persister cells by priming their metabolism, to implement novel 
strategies for treating infections by intracellular pathogens, which are more susceptible to some 
specific antibiotics when growing inside the cell, to develop antimicrobials with anti-biofilm activity, 
or to define novel targets, which inactivation would increase the susceptibility to antibiotics. 
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